Avantax Planning Partners, Inc. Abb Vie Inc. Transaction History

Avantax Planning Partners, Inc.

$2.78 Billion
Q3 2024

A detailed history of Avantax Planning Partners, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Avantax Planning Partners, Inc. holds 58,871 shares of ABBV stock, worth $10.6 Million. This represents 0.42% of its overall portfolio holdings.

Number of Shares

58,871

Previous 68,292 13.8%

Holding current value

$10.6 Million

Previous $11.7 Million 0.75%

% of portfolio

0.42%

Previous 0.38%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$163.84 - $199.33 $1.54 Million - $1.88 Million	-9,421 Reduced 13.8%	58,871 $11.6 Million
Q2 2024 Aug 09, 2024	BUY	$154.79 - $180.76 $43,960 - $51,335	284 Added 0.42%	68,292 $11.7 Million
Q1 2024 May 02, 2024	BUY	$159.82 - $182.1 $5.57 Million - $6.34 Million	34,843 Added 105.06%	68,008 $12.4 Million
Q4 2023 Feb 09, 2024	SELL	$137.6 - $154.97 $73,203 - $82,444	-532 Reduced 1.58%	33,165 $5.14 Million
Q3 2023 Nov 03, 2023	SELL	$133.59 - $154.65 $91,509 - $105,935	-685 Reduced 1.99%	33,697 $5.02 Million
Q2 2023 Jul 17, 2023	BUY	$132.51 - $164.9 $25,971 - $32,320	196 Added 0.57%	34,382 $4.63 Million
Q1 2023 Apr 20, 2023	BUY	$144.61 - $166.54 $192,331 - $221,498	1,330 Added 4.05%	34,186 $5.45 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $599,020 - $718,382	-4,331 Reduced 11.65%	32,856 $5.31 Million
Q3 2022 Oct 14, 2022	BUY	$134.21 - $153.93 $1.28 Million - $1.47 Million	9,534 Added 34.48%	37,187 $4.99 Million
Q2 2022 Jul 18, 2022	SELL	$137.62 - $174.96 $40,185 - $51,088	-292 Reduced 1.04%	27,653 $4.24 Million
Q1 2022 May 09, 2022	SELL	$131.98 - $163.75 $74,700 - $92,682	-566 Reduced 1.99%	27,945 $4.53 Million
Q4 2021 Jan 28, 2022	BUY	$107.43 - $135.93 $83,150 - $105,209	774 Added 2.79%	28,511 $3.86 Million
Q3 2021 Oct 27, 2021	BUY	$106.4 - $120.78 $20,428 - $23,189	192 Added 0.7%	27,737 $2.99 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $102,895 - $114,631	978 Added 3.68%	27,545 $3.1 Million
Q1 2021 May 06, 2021	BUY	$102.3 - $112.62 $2,659 - $2,928	26 Added 0.1%	26,567 $2.88 Million
Q4 2020 Feb 04, 2021	SELL	$80.49 - $108.67 $130,957 - $176,806	-1,627 Reduced 5.78%	26,541 $2.84 Million
Q3 2020 Oct 28, 2020	BUY	$85.91 - $100.83 $45,274 - $53,137	527 Added 1.91%	28,168 $2.47 Million
Q2 2020 Jul 15, 2020	SELL	$73.37 - $98.18 $8,657 - $11,585	-118 Reduced 0.43%	27,641 $2.71 Million
Q1 2020 Apr 27, 2020	SELL	$64.5 - $97.79 $786,577 - $1.19 Million	-12,195 Reduced 30.52%	27,759 $2.12 Million
Q4 2019 Jan 15, 2020	SELL	$72.13 - $90.25 $86,411 - $108,119	-1,198 Reduced 2.91%	39,954 $3.54 Million
Q3 2019 Nov 08, 2019	BUY	$62.98 - $75.72 $276,797 - $332,789	4,395 Added 11.96%	41,152 $3.12 Million
Q2 2019 Aug 07, 2019	BUY	$65.7 - $83.98 $1,051 - $1,343	16 Added 0.04%	36,757 $2.62 Million
Q1 2019 May 08, 2019	BUY	$77.14 - $90.79 $604,854 - $711,884	7,841 Added 27.13%	36,741 $2.96 Million
Q4 2018 Feb 14, 2019	BUY	$77.85 - $96.01 $2,024 - $2,496	26 Added 0.09%	28,900 $2.66 Million
Q3 2018 Nov 13, 2018	BUY	$88.91 - $98.84 $16,092 - $17,890	181 Added 0.63%	28,874 $2.73 Million
Q2 2018 Aug 13, 2018	BUY	$89.78 - $106.23 $111,596 - $132,043	1,243 Added 4.53%	28,693 $2.66 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $77,380 - $103,619	841 Added 3.16%	27,450 $2.6 Million
Q4 2017 Feb 09, 2018	SELL	$89.56 - $98.21 $441,172 - $483,782	-4,926 Reduced 15.62%	26,609 $2.57 Million
Q3 2017 Oct 19, 2017	BUY	$69.85 - $89.22 $2.2 Million - $2.81 Million	31,535	31,535 $2.8 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avantax Planning Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Avantax Planning Partners, Inc. with notifications on news.

Account

Avantax Planning Partners, Inc. Abb Vie Inc. Transaction History